Trodelvy (sacituzumab govitecan), First-in-class medicine to treat aggressive form of breast cancer
25 Ottobre 2021
EMA has recommended granting a marketing authorisation in the European Union (EU) for Trodelvy (sacituzumab govitecan), a first-in-class medicine to treat adult patients with unresectable (cannot be
